MEP13808A - Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders - Google Patents

Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders

Info

Publication number
MEP13808A
MEP13808A MEP-138/08A MEP13808A MEP13808A ME P13808 A MEP13808 A ME P13808A ME P13808 A MEP13808 A ME P13808A ME P13808 A MEP13808 A ME P13808A
Authority
ME
Montenegro
Prior art keywords
prevention
treatment
disorders
mesoprogestins
gynecological disorders
Prior art date
Application number
MEP-138/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MEP13808A publication Critical patent/MEP13808A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
MEP-138/08A 1999-08-31 2000-08-31 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders MEP13808A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31
PCT/US2000/023770 WO2001015679A2 (en) 1999-08-31 2000-08-31 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders

Publications (1)

Publication Number Publication Date
MEP13808A true MEP13808A (en) 2010-06-10

Family

ID=23524338

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-138/08A MEP13808A (en) 1999-08-31 2000-08-31 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders

Country Status (34)

Country Link
EP (1) EP1229906B1 (xx)
JP (1) JP2003535029A (xx)
KR (3) KR100755109B1 (xx)
AR (1) AR025457A1 (xx)
AT (1) ATE375160T1 (xx)
AU (1) AU781840B2 (xx)
BG (1) BG65817B1 (xx)
BR (1) BR0014161A (xx)
CA (1) CA2382580C (xx)
CO (1) CO5200772A1 (xx)
CZ (1) CZ2002704A3 (xx)
DE (1) DE60036723T2 (xx)
DK (1) DK1229906T3 (xx)
EA (1) EA007854B1 (xx)
EE (1) EE05172B1 (xx)
ES (1) ES2295050T3 (xx)
HR (1) HRP20020267A2 (xx)
HU (1) HUP0202429A3 (xx)
IL (1) IL148416A0 (xx)
LT (1) LT5034B (xx)
LV (1) LV12941B (xx)
ME (1) MEP13808A (xx)
MX (1) MXPA02002191A (xx)
NO (1) NO20020999L (xx)
NZ (1) NZ517471A (xx)
PE (1) PE20010578A1 (xx)
PL (1) PL198790B1 (xx)
PT (1) PT1229906E (xx)
RO (1) RO122179B1 (xx)
RS (1) RS50283B (xx)
SI (1) SI20852B (xx)
SK (1) SK287192B6 (xx)
UA (1) UA78184C2 (xx)
WO (1) WO2001015679A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2273061T3 (es) * 2002-08-02 2007-05-01 Schering Aktiengesellschaft Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal.
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
EP2455077B1 (en) * 2009-06-17 2014-06-11 National University Corporation Kumamoto University Prophylactic and/or therapeutic agent for dysmenorrhea
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
CN114728013A (zh) * 2019-09-23 2022-07-08 斯坦福大学托管董事会 延长妊娠以及月经或妊娠的并发症的治疗方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
EP1043315A1 (en) * 1994-12-22 2000-10-11 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5693646A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
PT806952E (pt) 1995-02-02 2003-08-29 Schering Ag Antagonistas da progesterona para a preparacao de medicamentos para o tratamento de hemorragias uterinas disfuncionais
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
AU710139B2 (en) * 1996-05-01 1999-09-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The 21-substituted progesterone derivatives as new antiprogestational agents
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
CA2359562A1 (en) * 1999-01-14 2000-07-20 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
AU4501800A (en) * 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
BG65817B1 (bg) 2010-01-29
RS50283B (sr) 2009-09-08
LT5034B (lt) 2003-07-25
NO20020999D0 (no) 2002-02-28
EA007854B1 (ru) 2007-02-27
SI20852B (sl) 2009-06-30
BG106442A (bg) 2002-09-30
HRP20020267A2 (en) 2004-04-30
PL353930A1 (en) 2003-12-15
LV12941B (en) 2003-06-20
YU14002A (sh) 2006-01-16
UA78184C2 (en) 2007-03-15
RO122179B1 (ro) 2009-02-27
DE60036723D1 (de) 2007-11-22
KR20070058023A (ko) 2007-06-07
NZ517471A (en) 2004-02-27
NO20020999L (no) 2002-03-14
KR20080066095A (ko) 2008-07-15
DK1229906T3 (da) 2008-02-11
SI20852A (sl) 2002-10-31
EP1229906A2 (en) 2002-08-14
EP1229906B1 (en) 2007-10-10
ATE375160T1 (de) 2007-10-15
KR20020027616A (ko) 2002-04-13
KR100755109B1 (ko) 2007-09-04
CA2382580C (en) 2009-05-19
EE05172B1 (et) 2009-06-15
KR100864547B1 (ko) 2008-10-20
BR0014161A (pt) 2002-05-21
IL148416A0 (en) 2002-09-12
AU6946600A (en) 2001-03-26
AU781840B2 (en) 2005-06-16
HUP0202429A2 (en) 2002-10-28
EE200200104A (et) 2003-04-15
SK2992002A3 (en) 2002-07-02
HUP0202429A3 (en) 2004-04-28
CZ2002704A3 (cs) 2003-02-12
JP2003535029A (ja) 2003-11-25
CA2382580A1 (en) 2001-03-08
PE20010578A1 (es) 2001-06-04
SK287192B6 (sk) 2010-02-08
LT2002031A (en) 2003-02-25
WO2001015679A3 (en) 2001-11-22
PT1229906E (pt) 2008-01-18
ES2295050T3 (es) 2008-04-16
PL198790B1 (pl) 2008-07-31
EA200200282A1 (ru) 2002-10-31
MXPA02002191A (es) 2002-09-30
DE60036723T2 (de) 2008-07-17
CO5200772A1 (es) 2002-09-27
AR025457A1 (es) 2002-11-27
WO2001015679A2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
US20120015917A1 (en) Use of Estrogenic Compounds in Combination with Progestogenic Compounds in Hormone-Replacement Therapy
MEP38008A (en) Drospirenone for hormone replacement therapy
EP1390041B1 (en) Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
DK0792152T3 (da) Fremgangsmåder til svangerskabsforebyggelse
Murphy et al. RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri
JP2010539153A5 (xx)
MEP13808A (en) Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders
Soaje et al. A modulatory role of endogenous opioids on prolactin secretion at the end of pregnancy in the rat
Brązert et al. Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology
Wrona et al. The role of levonorgestrel intrauterine systems in the treatment of symptomatic fibroids
Murray Natural progesterone: what role in women’s health care
PL201898B1 (pl) Zastosowanie antagonisty LH-RH w leczeniu endometriozy
EP1462106A1 (en) Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
van Casteren et al. Sex-and Gender-Specific Aspects of Migraine Treatment
SK101395A3 (en) Pharmaceutical anticonceptive agent and its use
Liu et al. Effect of some oral contraceptive steroids on the development of endometrial squamous metaplasia and cysts in rats
WO2003041719A1 (en) Method of contraception in mammalian females and pharmaceutical kit for use in such method
Allan et al. Progesterone receptor agonists and antagonists
BR0010070A (pt) Uso de org 33245, kit contraceptivo, meio combinado para a dosagem de um progestogênio e um antiprogestogênio, e, métodos de contracepção, e de tratamento de sangramento uterino irregular ou de ruptura em uma fêmea utilizando uma preparação somente de progestogênio
HRP20070360B1 (hr) Drospirenon za hormonsku nadomjesnu terapiju